Marinus Pharma Analyst Ratings
Marinus Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/08/2023 | 261.79% | Truist Securities | $32 → $25 | Maintains | Buy |
09/21/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | Overweight → Overweight |
09/20/2023 | 203.91% | RBC Capital | $20 → $21 | Maintains | Outperform |
09/20/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
08/11/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
08/11/2023 | 189.44% | RBC Capital | $21 → $20 | Maintains | Outperform |
08/11/2023 | 363.1% | Truist Securities | $42 → $32 | Maintains | Buy |
08/11/2023 | 88.13% | Ladenburg Thalmann | $17 → $13 | Maintains | Buy |
08/11/2023 | 189.44% | Baird | $24 → $20 | Maintains | Outperform |
08/11/2023 | 102.6% | Oppenheimer | → $14 | Downgrades | Outperform → Perform |
06/23/2023 | 305.21% | Cantor Fitzgerald | $28 → $28 | Reiterates | Overweight → Overweight |
06/14/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
05/30/2023 | 160.49% | JMP Securities | → $18 | Reiterates | Market Outperform → Market Outperform |
05/12/2023 | 507.81% | Truist Securities | $50 → $42 | Maintains | Buy |
05/12/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
04/25/2023 | 218.38% | RBC Capital | → $22 | Reiterates | → Outperform |
04/25/2023 | 102.6% | Oppenheimer | $12 → $14 | Maintains | Outperform |
03/08/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | → Overweight |
03/08/2023 | 218.38% | RBC Capital | $23 → $22 | Maintains | Outperform |
03/08/2023 | 160.49% | JMP Securities | $19 → $18 | Maintains | Market Outperform |
03/08/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | → Buy |
01/23/2023 | 232.85% | SVB Leerink | $27 → $23 | Maintains | Outperform |
01/20/2023 | 232.85% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
11/09/2022 | 247.32% | Baird | $32 → $24 | Maintains | Outperform |
03/22/2022 | 623.59% | Truist Securities | $35 → $50 | Maintains | Buy |
03/22/2022 | 218.38% | JMP Securities | $21 → $22 | Maintains | Market Outperform |
03/22/2022 | 290.74% | SVB Leerink | $30 → $27 | Maintains | Outperform |
12/20/2021 | 334.15% | SVB Leerink | $32 → $30 | Maintains | Outperform |
09/30/2020 | 406.51% | Truist Securities | → $35 | Initiates Coverage On | → Buy |
09/28/2020 | 406.51% | HC Wainwright & Co. | $9 → $35 | Maintains | Buy |
09/15/2020 | 15.77% | SVB Leerink | $6 → $8 | Maintains | Outperform |
07/01/2020 | 30.25% | HC Wainwright & Co. | $6 → $9 | Maintains | Buy |
07/01/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
05/05/2020 | -13.17% | Cantor Fitzgerald | $7 → $6 | Reiterates | → Overweight |
01/10/2020 | -13.17% | HC Wainwright & Co. | $5 → $6 | Reiterates | → Buy |
12/20/2019 | -13.17% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
10/18/2019 | 1.3% | Cantor Fitzgerald | → $7 | Assumes | → Overweight |
09/03/2019 | -27.64% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
03/05/2019 | 44.72% | Jefferies | → $10 | Initiates Coverage On | → Buy |
02/27/2019 | -27.64% | Mizuho | $13 → $5 | Downgrades | Buy → Neutral |
02/06/2019 | 44.72% | Leerink Swann | → $10 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/08/2023 | 261.79% | Truist 证券 | 32 美元 → 25 美元 | 维护 | 买 |
09/21/2023 | 305.21% | 坎托·菲茨杰拉德 | → 28 美元 | 重申 | 超重 → 超重 |
09/20/2023 | 203.91% | 加拿大皇家银行资本 | 20 美元 → 21 美元 | 维护 | 跑赢大盘 |
09/20/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 购买 → 购买 |
08/11/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 购买 → 购买 |
08/11/2023 | 189.44% | 加拿大皇家银行资本 | 21 美元 → 20 美元 | 维护 | 跑赢大盘 |
08/11/2023 | 363.1% | Truist 证券 | 42 美元 → 32 美元 | 维护 | 买 |
08/11/2023 | 88.13% | 拉登堡塔尔曼 | 17 美元 → 13 美元 | 维护 | 买 |
08/11/2023 | 189.44% | 贝尔德 | 24 美元 → 20 美元 | 维护 | 跑赢大盘 |
08/11/2023 | 102.6% | 奥本海默 | → 14 美元 | 降级 | 跑赢大盘 → 表现 |
06/23/2023 | 305.21% | 坎托·菲茨杰拉德 | 28 美元 → 28 美元 | 重申 | 超重 → 超重 |
06/14/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 购买 → 购买 |
05/30/2023 | 160.49% | JMP 证券 | → 18 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
05/12/2023 | 507.81% | Truist 证券 | 50 美元 → 42 美元 | 维护 | 买 |
05/12/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 购买 → 购买 |
2023 年 4 月 25 日 | 218.38% | 加拿大皇家银行资本 | → 22 美元 | 重申 | → 跑赢大盘 |
2023 年 4 月 25 日 | 102.6% | 奥本海默 | 12 美元 → 14 美元 | 维护 | 跑赢大盘 |
03/08/2023 | 305.21% | 坎托·菲茨杰拉德 | → 28 美元 | 重申 | → 超重 |
03/08/2023 | 218.38% | 加拿大皇家银行资本 | 23 美元 → 22 美元 | 维护 | 跑赢大盘 |
03/08/2023 | 160.49% | JMP 证券 | 19 美元 → 18 美元 | 维护 | 市场表现跑赢大盘 |
03/08/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | → 购买 |
2023 年 1 月 23 日 | 232.85% | SVB Leerink | 27 美元 → 23 美元 | 维护 | 跑赢大盘 |
01/20/2023 | 232.85% | 加拿大皇家银行资本 | → 23 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
11/09/2022 | 247.32% | 贝尔德 | 32 美元 → 24 美元 | 维护 | 跑赢大盘 |
03/22/2022 | 623.59% | Truist 证券 | 35 美元 → 50 美元 | 维护 | 买 |
03/22/2022 | 218.38% | JMP 证券 | 21 美元 → 22 美元 | 维护 | 市场表现跑赢大盘 |
03/22/2022 | 290.74% | SVB Leerink | 30 美元 → 27 美元 | 维护 | 跑赢大盘 |
2021 年 12 月 20 日 | 334.15% | SVB Leerink | 32 美元 → 30 美元 | 维护 | 跑赢大盘 |
09/30/2020 | 406.51% | Truist 证券 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
09/28/2020 | 406.51% | HC Wainwright & Co. | 9 美元 → 35 美元 | 维护 | 买 |
2020 年 9 月 15 日 | 15.77% | SVB Leerink | 6 美元 → 8 美元 | 维护 | 跑赢大盘 |
07/01/2020 | 30.25% | HC Wainwright & Co. | 6 美元 → 9 美元 | 维护 | 买 |
07/01/2020 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
05/05/2020 | -13.17% | 坎托·菲茨杰拉德 | 7 美元 → 6 美元 | 重申 | → 超重 |
2020 年 10 月 1 日 | -13.17% | HC Wainwright & Co. | 5 美元 → 6 美元 | 重申 | → 购买 |
12/20/2019 | -13.17% | 奥本海默 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
10/18/2019 | 1.3% | 坎托·菲茨杰拉德 | → 7 美元 | 假设 | → 超重 |
2019 年 3 月 9 日 | -27.64% | HC Wainwright & Co. | → 5 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 5 月 3 日 | 44.72% | 杰富瑞集团 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
02/27/2019 | -27.64% | 瑞穗市 | 13 美元 → 5 美元 | 降级 | 买入 → 中性 |
02/06/2019 | 44.72% | Leerink Swann | → 10 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Marinus Pharma (MRNS)?
Marinus Pharma(MRNS)的目标价格是多少?
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by Truist Securities on November 8, 2023. The analyst firm set a price target for $25.00 expecting MRNS to rise to within 12 months (a possible 261.79% upside). 24 analyst firms have reported ratings in the last year.
Truist Securities于2023年11月8日公布了Marinus Pharma(纳斯达克股票代码:MRNS)的最新目标股价。该分析公司将目标股价定为25美元,预计MRNS将在12个月内升至12个月内(可能上涨261.79%)。去年有24家分析公司公布了评级。
What is the most recent analyst rating for Marinus Pharma (MRNS)?
分析师对Marinus Pharma(MRNS)的最新评级是多少?
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by Truist Securities, and Marinus Pharma maintained their buy rating.
Truist Securities提供了Marinus Pharma(纳斯达克股票代码:MRNS)的最新分析师评级,Marinus Pharma维持买入评级。
When is the next analyst rating going to be posted or updated for Marinus Pharma (MRNS)?
Marinus Pharma(MRNS)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Marinus Pharma的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Marinus Pharma的最新评级是在2023年11月8日公布的,因此您应该预计下一个评级将在2024年11月8日左右公布。
Is the Analyst Rating Marinus Pharma (MRNS) correct?
分析师对 Marinus Pharma (MRNS) 的评级正确吗?
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a maintained with a price target of $32.00 to $25.00. The current price Marinus Pharma (MRNS) is trading at is $6.91, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Marinus Pharma(MRNS)评级保持不变,目标股价为32.00美元至25.00美元。Marinus Pharma(MRNS)目前的交易价格为6.91美元,超出了分析师的预期区间。